Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate expectations. This scenario led to a shift in investor focus toward sectors such as energy, defense, and AI-linked stocks, while the fund’s core exposure to healthcare, consumer, and idiosyncratic industrials lagged. Despite this setback, the firm maintains a constructive long-term outlook, suggesting that the current market volatility and consensus-driven market narratives are creating attractive opportunities in out-of-favor sectors where it continues to find compelling valuations and expects eventual mean reversion to drive future returns. In addition, you can check the Fund’s top five holdings to determine its best picks for 2026.
In its first-quarter 2026 investor letter, Minot Light Capital Appreciation Fund highlighted stocks like MaxCyte, Inc. (NASDAQ:MXCT). MaxCyte, Inc. (NASDAQ:MXCT) is a cell-engineering company providing electroporation technology platforms for cell therapy development and biomedical research. The one-month return of MaxCyte, Inc. (NASDAQ:MXCT) was -2.72% while its shares traded between $0.6434 and $2.4000 over the last 52 weeks. On May 12, 2026, MaxCyte, Inc. (NASDAQ:MXCT) stock closed at approximately $0.82 per share, with a market capitalization of about $88.08 million.
Minot Light Capital Appreciation Fund stated the following regarding MaxCyte, Inc. (NASDAQ:MXCT) in its Q1 2026 investor letter:
“When we look at our other top detractors this quarters, you will hear a similar theme around former leading gainers becoming detractors after large-stock runs and quarterly results that disappointed the Street. Another similar theme is stocks falling well below what we deem to be any reasonable valuation level, where we keep adding to the position to make it really count when things turn. That would be the case with MaxCyte, Inc. (NASDAQ:MXCT), which is a company with a manageable current burn rate, a leading position in ex-vivo gene editing equipment, and a series of current and hopefully future royalty streams associated with a number of drugs being developed with its equipment and consumables. Shares of MaxCyte fell below half of net cash on the balance sheet last quarter, which also assigned no value to its core business or future royalty cashflows. In turn, we have made it a top-five position for the fund.”
MaxCyte, Inc. (NASDAQ:MXCT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 15 hedge fund portfolios held MaxCyte, Inc. (NASDAQ:MXCT) at the end of the fourth quarter, which was 13 in the previous quarter. While we acknowledge the risk and potential of MaxCyte, Inc. (NASDAQ:MXCT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MaxCyte, Inc. (NASDAQ:MXCT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered MaxCyte, Inc. (NASDAQ:MXCT) and shared the list of best penny stocks under $1 to buy. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. This article is originally published at Insider Monkey.
